ECE2024 Poster Presentations Late-Breaking (77 abstracts)
Activating somatic ESR1 mutation in an aggressive prolactinoma
Ticiana Silva 1 , Jacobo Buelvas Mebarak 2 , John C. Magnotto 2 , George A. Stamatiades 2 , Yanan Kuang 3 , Cloud Paweletz 3 , Edward R. Laws 4 , Rona Stephanie Carroll 2 , Rinath Jeselsohn 3 , Dipika Mohan 5 , Antonio Marcondes Lerario 6 , Minh-Tam Truong 7 , Wenya Linda Bi 4 , David A. Reardon 3 , David M. Meredith 8 , Ursula Kaiser 2 & Ana Paula Abreu 1
1Brigham and Women’s Hospital and Harvard Medical School, Department of Internal Medicine, Division of Endocrinology, Diabetes and Hypertension, Boston, United States; 2Brigham and Women’s Hospital and Harvard Medical School, Department of Internal Medicine, Division of Endocrinology, Diabetes and Hypertension, Boston, United States; 3Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, United States; 4Brigham and Women’s Hospital and Harvard Medical School, Department of Neurosurgery, Boston, United States; 5Washington University School of Medicine, Department of Medicine, St. Louis, United States; 6University of Michigan, Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, Ann Arbor, United States; 7Boston University Chobanian & Avedisian School of Medicine, Department of Radiation Oncology, Boston, United States; 8Brigham and Women’s Hospital and Harvard Medical School, Department of Pathology, Boston, United States
Introduction: Prolactinomas are benign tumors usually well controlled with dopamine agonists; few progress on medical therapy through unclear molecular mechanisms. Although the SF3B1 mutation has been recently associated with aggressive prolactinomas, in most cases, no genetic mutations have been reported. We aimed to identify somatic genetic alterations associated with prolactinomas using a gene panel.
Method and Results: Oncopanel, a massively parallel sequencing panel, was performed to identify somatic genomic variants and copy number variation (CNV) in a cohort of 20 patients with prolactinomas (age, mean &mplus; SD 38.6 &mplus; 14.49 years; 12 women). 40% of our patients who underwent surgery were resistant to dopamine agonists. None of our patients had metastatic disease. We identified a somatic ESR1 (encoding estrogen receptor alpha) mutation (p.y537S) in a post-menopausal woman with a recurrent prolactinoma in DNA obtained from her fourth surgery. No SF3B1 variants or other pathogenic variants were identified in this cohort. The median CNV events was 46 events (IQR: 1-80) with 64% gene amplification and 36% gene losses. The prolactinoma harboring the ESR1Y537S had 233 CNV events consistent with a highly disrupted genome and much higher than the remaining of our cohort samples. We then sought to investigate if there was circulating cell-free DNA. We were able to identify ESR1Y537S in peripheral blood using droplet digital PCR, indicating high tumor shredding, which is not commonly seen in pituitary adenomas and raises the question of the benign nature of this tumor. ESR1Y537S is a hotspot mutation in metastatic breast cancer. ESR1Y537S confers resistance to classic hormonal treatment in breast cancer by activating the receptor independent of ligand binding. This results in high cell proliferation and confers an advantage over cells expressing wild-type estrogen receptors. Elacestrant, a second-line ER degrader, increases overall progression-free survival in patients with resistant breast cancer and ESR1Y537S. Given the lack of response to multimodality therapies, elacestrant was initiated after completition of the third cycle of radiotherapy in this patient with aggressive prolactinoma harboring ESR1Y537S. The combination of radiotherapy with this personalized treatment was able to control tumor growth and significantly reduce prolactin levels after years without adequate control.
Conclusion: ESR1 regulates lactotroph differentiation and proliferation. Our data supported a role for ESR1Y537S in the unusually aggressive behavior of this patient’s prolactinoma in the postmenopausal setting. Molecular profiling revealing the ESR1Y537S mutation allowed us to use targeted therapy to promote control of a previously resistant prolactinoma.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more